Reactivity and communication of health authorities toward health professionals: A public health priority;Réactivité et communication des décisions de pharmacovigilance des autorités de santé vers les professionnels de santé: Exemples du pergolide et du célécoxib

Therapie

Volumn 62, Issue 6, 2007, Pages 513-517

  Victorri Vigneau, Caroline ^a   Marais, Marie ^a   Veyrac, Gwenaëlle ^a   Chaslerie, Anicet ^b   Pivette, Jacques ^b   Jolliet, Pascale ^a  

^a INSTITUT DE BIOLOGIE   (France)

^b Serv Medical de l'Assurance Maladie   (France)

Author keywords

Celecoxib; Communication; Health authorities; Impact; Pergolide

Indexed keywords

CELECOXIB; LEVODOPA; PERGOLIDE; PERGOLIDE MESILATE; ROFECOXIB;

ARTICLE; CARDIOVASCULAR RISK; CONTROLLED STUDY; DRUG INDICATION; DRUG INFORMATION; DRUG SURVEILLANCE PROGRAM; FEMALE; HEALTH CARE MANAGEMENT; HEALTH CARE PERSONNEL; HEALTH PRACTITIONER; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL PRACTICE; OSTEOARTHRITIS; PARKINSON DISEASE; PATIENT MONITORING; PRIORITY JOURNAL; RECTUM POLYP; RHEUMATOID ARTHRITIS; VALVULAR HEART DISEASE;

EID: 48749113103     PISSN: 00405957     EISSN: None     Source Type: Journal    
DOI: 10.2515/therapie:2007064     Document Type: Article

References (6)

1. Thirion X, Lapierre V, Micallef J, et al. Buprenorphine prescription by general practioners in a French region. Drug Alcohol Depend 2002; 65: 197-204
2. Victorri-Vigneau C, Basset G, Bourin M, Jolliet P. Impacts de la nouvelle réglementation du flunitrazépam sur la consommation d'hypnotiques. Therapie 2003; 58(5): 425-430
3. Frauger E, Thirion X, Chanut C, et al. Misuse of trihexyphénidyle (Artane®, Parkinane®): recent trends. Therapie 2003; 58(6): 541-7
4. Micallef J, Pradel V, Thirion X, et al. Use of the Health Insurance Database by the Centers for Evaluation and Information on Pharmacodependance: examples, interest and future prospects. Therapie 2004; 59(6): 581-8
5. Victorri-Vigneau C, Basset G, Jolliet P. How a novel programme for increasing awareness of health professionals resulted in a 14% decrease in patients using excessive doses of psychotropic drugs in Western France. European Journal of Clinical Pharmacology 2006; 62(4): 311-6
6. http://afssaps.sante.fr/htm/10/avk/impact.htm consulté le 20 février 2006